Pharmaceuticals Company Gets USFDA Approval For Phytonadione Injectable Emulsion
The stock gave multibagger returns of 190 per cent in 2 years and a whopping 500 per cent in 5 years.
Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Phytonadione Injectable Emulsion USP, 10 mg/mL, Single Dose Vial, a generic therapeutic equivalent version of the Reference Listed Drug (RLD) VITAMIN K1 Injection, from Hospira Inc.
Phytonadione Injectable Emulsion possesses the same type and degree of activity as does naturally-occurring vitamin K and is indicated for coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. According to IQVIATM (IMS Health), Phytonadione Injectable Emulsion had US sales of approximately USD 18.5 million for the 12 months ending February 2025.
Today, shares of Caplin Point Laboratories Ltd gained 1.23 per cent to Rs 1,913.35 per share from its previous closing of Rs 1,890.15 per share. The stock’s 52-week high is Rs 2,636 per share and its 52-week low is Rs 1,221 per share.
DSIJ's ‘Mid Bridge’ service recommends well researched Mid-Cap stocks for smart investing. If this interests you, download the service details here.
Caplin Point Laboratories Limited is a fast-growing pharmaceutical company with a unique business model catering predominantly to the emerging markets of Latin America and Africa. The Company has state-of-the-art manufacturing facilities that cater to a complete range of finished dosage forms. Caplin Point is one of the few companies to show consistent high-quality growth in cash flows, Profitability and Revenues over the last 15 years.
The company has a market cap of over Rs 14,000 crore and has delivered good profit growth of 21.2 per cent CAGR over the last 5 years. The company's shares have an ROE of 25 per cent and an ROCE of 26 per cent. The stock gave multibagger returns of 190 per cent in 2 years and a whopping 500 per cent in 5 years. Investors should keep an eye on this mid-cap pharma stock.
Disclaimer: The article is for informational purposes only and not investment advice.